Litigation Details for Genentech, Inc. v. Aurobindo Pharma Limited (D. Del. 2019)

Genentech, Inc. v. Aurobindo Pharma Limited (D. Del. 2019)

Docket		Date Filed	2019-01-14
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	8,013,002
Link to Docket	External link to docket

Details for Genentech, Inc. v. Aurobindo Pharma Limited (D. Del. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-01-14	81	Patent/Trademark Report to Commissioner of Patents	B1 ;7,767,700 B2; 7,816,383 B1 ;7,910,610 B1; 8,013,002 B2 ;8,084,475 B2; 8,318,780 B2 ;8,420,674 B2; …Amended Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,566,729 B1; … 14 January 2019 1:19-cv-00078 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Genentech, Inc. v. Aurobindo Pharma Limited: Litigation Analysis

Last updated: February 17, 2026

This report analyzes the patent litigation between Genentech, Inc. and Aurobindo Pharma Limited, specifically Case No. 1:19-cv-00078, concerning Aurobindo's abbreviated new drug application (ANDA) for a generic version of Genentech's lung cancer treatment, Avastin (bevacizumab). The dispute centers on alleged infringement of Genentech's U.S. Patent No. 8,735,360.

What is the Core Legal Dispute?

The central legal dispute revolves around Aurobindo Pharma Limited's attempt to introduce a generic version of bevacizumab, a biologic drug marketed by Genentech as Avastin. Genentech alleges that Aurobindo's filing of an ANDA infringes U.S. Patent No. 8,735,360, which Genentech holds. This patent is identified as a “skinny label” patent, meaning it claims specific uses for the drug that are not listed in the FDA-approved labeling of the branded product at the time of patent issuance.

Key Patent at Issue: U.S. Patent No. 8,735,360

U.S. Patent No. 8,735,360 was issued on May 29, 2014, to Genentech, Inc. The patent claims methods of treating non-small cell lung cancer (NSCLC) with a combination therapy. Specifically, the claims describe a method for treating patients with metastatic non-squamous non-small cell lung cancer using a chemotherapeutic agent in combination with bevacizumab.

The critical aspect of this patent is that at the time of its issuance, the FDA-approved labeling for Avastin did not explicitly list this specific combination therapy for NSCLC. This distinction is crucial in Hatch-Waxman ANDA litigation, particularly concerning the concept of “induced infringement” and the scope of patent claims relative to FDA-approved indications.

The ANDA Filing and Genentech's Response

Aurobindo Pharma Limited filed an ANDA seeking approval to market a generic version of bevacizumab. Under the Hatch-Waxman Act, an ANDA filer must certify that their proposed generic drug does not infringe any valid and unexpired patents listed in the FDA's Orange Book for the reference listed drug (RLD).

Genentech asserted that Aurobindo's ANDA filing, by seeking approval for a drug that could be used for the patented method of treatment, constituted induced infringement of U.S. Patent No. 8,735,360. Genentech argued that Aurobindo would actively induce physicians and patients to use the generic bevacizumab in a manner covered by the patent claims, even if the generic label did not explicitly mention the patented use.

What are the Key Legal Arguments?

Genentech's primary argument is based on induced infringement. They contend that Aurobindo, by seeking to market a generic bevacizumab, is intentionally encouraging others to infringe the '360 patent. Aurobindo, conversely, argues that its ANDA is for a drug approved for indications for which the patent does not claim protection, and therefore, it is not inducing infringement.

Genentech's Induced Infringement Claim

Genentech's claim of induced infringement hinges on proving that Aurobindo possessed the specific intent to induce infringement. This requires demonstrating that Aurobindo knew of the '360 patent and that its actions would encourage or cause others to infringe. Genentech likely points to the fact that bevacizumab is a well-known treatment for NSCLC, and that physicians, even with a generic label, would likely prescribe it for the patented use, thereby infringing the patent.

The "skinny label" aspect of the patent is central to this argument. Genentech claims that the patent covers a specific method of use that is not in the current Avastin label. Thus, any sale of bevacizumab for that specific use, if induced by Aurobindo, would be infringement.

Aurobindo's Defenses

Aurobindo's defense likely includes arguments that:

1. No Direct Infringement: Aurobindo is not directly infringing the patent because its ANDA seeks approval for indications for which the patent does not claim protection or for which the patent has expired.
2. Lack of Inducement Intent: Aurobindo lacks the specific intent to induce infringement. The company is merely seeking to compete in the market for approved indications.
3. Patent Invalidity: Aurobindo may also challenge the validity of the '360 patent on grounds such as obviousness or lack of enablement.
4. No Induced Use: Even if physicians use the drug for the patented indication, this use is not induced by Aurobindo’s labeling or marketing efforts for the ANDA.

What is the Procedural History of the Case?

The litigation commenced in January 2019. The case has proceeded through various stages, including discovery, motion practice, and ultimately, a bench trial.

Timeline of Key Events

• January 17, 2019: Genentech, Inc. filed a complaint against Aurobindo Pharma Limited and Aurobindo Pharma USA, Inc. in the U.S. District Court for the District of Delaware, alleging infringement of U.S. Patent No. 8,735,360.
• March 2019: Aurobindo filed its answer, denying infringement and asserting counterclaims.
• Throughout 2019-2020: The parties engaged in discovery and filed various motions, including motions for summary judgment.
• October 2020: The District Court held a bench trial.
• December 16, 2020: The District Court issued its order, ruling in favor of Aurobindo, finding no induced infringement.
• January 14, 2021: Genentech filed a notice of appeal to the U.S. Court of Appeals for the Federal Circuit.
• May 4, 2022: The Federal Circuit affirmed the District Court's decision, upholding the finding of no induced infringement.
• August 2, 2022: Genentech filed a petition for panel rehearing and rehearing en banc, which was denied.
• November 2022: The mandate from the Federal Circuit was issued, finalizing the appeal.

What Was the District Court's Ruling?

The District Court found that Aurobindo did not induce infringement of U.S. Patent No. 8,735,360. The court concluded that Genentech failed to prove that Aurobindo possessed the specific intent to induce infringement.

Key Findings of the District Court

The District Court's decision, issued on December 16, 2020, focused on the elements required to prove induced infringement.

• No Direct Infringement by Aurobindo: The court found that Aurobindo, by filing its ANDA and seeking approval for indications not covered by the '360 patent, was not directly infringing the patent.
• Failure to Prove Specific Intent: Genentech's primary hurdle was proving Aurobindo's specific intent to induce infringement. The court held that Genentech did not present sufficient evidence to establish that Aurobindo intended for physicians to use its generic bevacizumab for the method of treatment claimed in the '360 patent.
• "Skinny Label" Implications: While acknowledging the "skinny label" nature of the patent, the court found that this alone was not enough to prove induced infringement. The burden remained on Genentech to demonstrate Aurobindo's affirmative intent to encourage infringement of the patented use. The court noted that physicians may independently choose to prescribe a drug off-label for a patented use, and this independent action does not automatically translate to induced infringement by the manufacturer if the manufacturer has not actively encouraged such use.

What Was the Federal Circuit's Decision on Appeal?

The U.S. Court of Appeals for the Federal Circuit affirmed the District Court's ruling, agreeing that Genentech failed to establish induced infringement. The Federal Circuit’s decision, issued on May 4, 2022, provided further clarity on the standard for induced infringement in the context of generic drug approvals and "skinny label" patents.

Key Aspects of the Federal Circuit's Affirmation

The Federal Circuit's decision reinforced the high bar for proving induced infringement, particularly when the alleged infringer has not directly infringed and the patent is for a method of use not explicitly in the product's label.

• Standard for Induced Infringement: The court reiterated that to prove induced infringement, a patent holder must show that the accused infringer actively and knowingly aided and abetted another's direct infringement. This requires proof of specific intent to induce infringement.
• "Skinny Label" Limitation: The Federal Circuit agreed that the existence of a "skinny label" patent does not automatically create liability for induced infringement. Genentech had to demonstrate that Aurobindo took affirmative steps to encourage physicians to use its generic bevacizumab for the patented indication.
• Evidence of Intent: The court found that Genentech’s evidence did not sufficiently demonstrate Aurobindo's specific intent. The fact that the drug has a known efficacy for the patented use, and that physicians might prescribe it for that use, was not enough. Genentech needed to show that Aurobindo’s actions were specifically aimed at encouraging that patented use.
• No Evidence of Encouragement: The appellate court found no evidence that Aurobindo's labeling, marketing materials, or other communications were designed to promote or encourage the use of its generic bevacizumab for the specific method of treatment claimed in the '360 patent. The generic product was approved for indications that did not infringe the patent.

What are the Implications for Other "Skinny Label" Cases?

The Federal Circuit's decision in Genentech v. Aurobindo has significant implications for future litigation involving "skinny label" patents and generic drug approvals. It clarifies and potentially raises the bar for patent holders seeking to enforce such patents against ANDA filers.

Impact on Patent Enforcement Strategies

• Higher Burden of Proof for Inducement: Patent holders must present stronger evidence of specific intent to induce infringement. This may require demonstrating direct evidence of Aurobindo's actions aimed at encouraging the patented use, beyond the mere existence of the patented use and the availability of the generic drug.
• Focus on Manufacturer's Conduct: The ruling emphasizes that the focus will be on the ANDA filer's conduct, not solely on the potential actions of prescribers or the known efficacy of the drug for a particular indication.
• Limited Scope of "Skinny Label" Protection: The decision suggests that "skinny label" patents may offer less protection against generic competition if the patent holder cannot demonstrate active inducement by the ANDA filer. The strategy of obtaining a patent for a method of use not in the RLD's label may become less effective as a barrier to generic entry without further affirmative actions by the ANDA filer.
• Strategic Considerations for ANDA Filers: Generic manufacturers can take comfort in the clarity provided by this ruling. They can continue to pursue ANDA approvals for indications not covered by "skinny label" patents, provided their marketing and labeling remain focused on those approved indications.
• Potential for Pre-Trial Dismissal: The heightened standard for proving intent may lead to more successful motions to dismiss or summary judgment rulings in favor of ANDA filers if patent holders cannot adequately plead or demonstrate intent early in the litigation.

What are the Broader Market Consequences?

This litigation outcome has tangible consequences for the market dynamics of bevacizumab and potentially other biologic drugs.

Market Impact on Bevacizumab

• Increased Generic Competition: The Federal Circuit's decision clears the path for Aurobindo and potentially other generic manufacturers to launch their versions of bevacizumab for the approved indications. This is expected to lead to increased price competition.
• Impact on Genentech's Revenue: The entry of more generic competitors will likely reduce Genentech's market share and revenue derived from Avastin.
• Accessibility of Treatment: Increased generic availability can lead to lower drug prices, potentially improving patient access to bevacizumab for approved uses.

Precedent for Biosimilar Litigation

While bevacizumab is an antibody and thus potentially subject to biosimilar regulations under the BPCIA, the dispute here was framed as a Hatch-Waxman ANDA case. However, the principles discussed regarding induced infringement and method-of-use patents can have relevance in future biosimilar litigation, particularly if biosimilar applicants seek to market their products for indications covered by innovator method-of-use patents. The clarity on induced infringement and the onus on the patent holder to prove specific intent will be crucial in future cases.

Key Takeaways

• Genentech, Inc. v. Aurobindo Pharma Limited, Case No. 1:19-cv-00078, involved Genentech's assertion of induced infringement against Aurobindo's ANDA for generic bevacizumab, based on U.S. Patent No. 8,735,360.
• The patent in question was a "skinny label" patent, claiming a method of treatment not explicitly listed in the reference drug's label.
• Both the District Court and the Federal Circuit ruled in favor of Aurobindo, finding no induced infringement.
• The courts determined that Genentech failed to prove Aurobindo possessed the specific intent required to induce infringement.
• The Federal Circuit affirmed that the existence of a "skinny label" patent does not automatically establish induced infringement; patent holders must demonstrate active encouragement of the patented use by the ANDA filer.
• This ruling raises the evidentiary bar for patent holders seeking to enforce "skinny label" patents against generic drug manufacturers.
• The decision is likely to accelerate generic competition for bevacizumab and has broader implications for similar patent litigation involving method-of-use claims.

Frequently Asked Questions

1. What was the primary reason the courts ruled against Genentech in this case? The primary reason was Genentech's failure to prove that Aurobindo Pharma Limited possessed the specific intent to induce infringement of U.S. Patent No. 8,735,360.
2. Does the ruling mean "skinny label" patents are no longer enforceable? No, "skinny label" patents remain enforceable, but the ruling clarifies that patent holders must provide stronger evidence of the ANDA filer's active and specific intent to induce infringement, beyond merely selling a drug that could be used for the patented indication.
3. What is the difference between direct infringement and induced infringement in this context? Direct infringement occurs when a party performs the patented act itself. Induced infringement occurs when a party actively and intentionally encourages or causes another party to directly infringe the patent. In this case, Aurobindo was not accused of directly infringing, but of inducing others (physicians and patients) to infringe.
4. How does this case affect the pricing and availability of generic bevacizumab? The ruling likely facilitates the entry of generic bevacizumab into the market, which is expected to increase competition and potentially lower prices for patients and healthcare systems.
5. Could this ruling impact the development of biosimilars? While this was an ANDA case, the legal principles surrounding induced infringement and the burden of proof for intent are relevant to biosimilar litigation. The decision reinforces the need for clear evidence of intent to induce infringement in cases involving method-of-use patents.

Citations

[1] Genentech, Inc. v. Aurobindo Pharma Limited, No. 1:19-cv-00078 (D. Del. Dec. 16, 2020). [2] Genentech, Inc. v. Aurobindo Pharma Limited, No. 21-1384 (Fed. Cir. May 4, 2022). [3] United States Patent No. 8,735,360.